Development of a Panel of Biomarkers for Differential Diagnosis of Multiple Sclerosis

Demyelinating diseases are a group of heterogeneous pathologies that affect the nervous system and reduce the quality of life. One of such diseases is multiple sclerosis (MS), an inflammatory autoimmune neurodegenerative disease of the central nervous system (CNS). At the initial stages, MS can mimi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Doklady. Biochemistry and biophysics Ročník 519; číslo 1; s. 593 - 596
Hlavní autoři:	Ovchinnikova, L. A., Dzhelad, S. S., Simaniv, T. O., Zakharova, M. N., Lomakin, Y. A., Gabibov, A. G., Illarioshkin, S. N.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Moscow Pleiades Publishing 01.12.2024 Springer Nature B.V
Témata:	Accuracy Adult Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - diagnosis Antibodies Antigens Autoimmune diseases Biochemistry Biochemistry, Biophysics, and Molecular Biology Biological and Medical Physics Biomarkers Biomarkers - blood Biomarkers - metabolism Biomedical and Life Sciences Biophysics Central nervous system Conflicts of interest Demyelinating diseases Demyelination Diagnosis, Differential Differential diagnosis Disease Epstein-Barr virus Female Humans Kinases Life Sciences Male Middle Aged Molecular Biology Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - diagnosis Multiple Sclerosis - metabolism Nervous system Neurodegeneration Neurodegenerative diseases Neuromyelitis Neuromyelitis Optica - blood Neuromyelitis Optica - diagnosis Peptides Proteins Quality of life Spinal cord EBV autoantibodies demyelinating diseases multiple sclerosis MS Epstein–Barr virus
ISSN:	1607-6729, 1608-3091, 1608-3091
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Demyelinating diseases are a group of heterogeneous pathologies that affect the nervous system and reduce the quality of life. One of such diseases is multiple sclerosis (MS), an inflammatory autoimmune neurodegenerative disease of the central nervous system (CNS). At the initial stages, MS can mimic some infectious, neoplastic, genetic, metabolic, vascular, and other pathologies. Accurate differential diagnosis of this disease is important to improve the quality of life of patients and reduce possible irreversible damage to the central nervous system. In this work, we confirmed the possibility of using our previously proposed candidate panel of MS biomarkers to distinguish MS from neuromyelitis optica spectrum disorder (NMOSD) and amyotrophic lateral sclerosis (ALS). We have shown that our proposed panel (SPTAN1 601-644 + PRX 451-494 + PTK6 301-344 + LMP1 285-330 ) allows us to distinguish MS from ALS (AUC = 0.796) and NMOSD (AUC = 0.779).
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1607-6729 1608-3091 1608-3091
DOI:	10.1134/S160767292460060X